Biotie Therapies -- Finnisch Power Zum Schleuderpreis - 500 Beiträge pro Seite

[BrauchGeld]

Hallo

Hab ein grossteil meiner Cenes Pharma aktien verkauft und in Biotie umgeschichtet und wurde prompt am freitag mit 40% plus belohnt !
Trotz 40% plus ist Biotie nur mit 53 mio€ bewertet !
Hier eine Kurzfassung über diese Hammeraktie :

Biotie Therapies
Marktkap.: 53 mio€
Kurs: 1,04 €

Nalmefene gegen Alkoholabhängigkeit -- Phase 3 erfolgreich abgeschlossen und hat bereits Zulassungsantrag bei der MHRA eingereicht .
Biotie erwartet gegen ende 2007 die zulassung für U.K. weitere europäische länder dürften anschliessend folgen .

Nalmefene gegen Spielsucht -- befindet sich gerade in Phase 2/3 ergebnisse werden für Dezember 2006 erwartet

Nalmefene gegen Nikotinsucht -- befindet sich in Phase 2 ergebnisse werden ebenfalls für Dezember 2006 erwartet

Biotie besitzt ab zulassung 10 jahre markt exklusivität in Europa und 6 jahre in Japan .

Somaxon hält für Nalmefene die Noradamerika rechte .

Ein kleiner vergleich Alkermes(1,6 mrd$ marktkap.!!!) hat mit Cephalon einen deal im wert von 490 mio$ für Vivitrol(Alkoholabhängigkeit) abgeschlossen während Biotie für lächerliche 53 mio€ zuhaben ist !


Homepage:
www.biotie.com

Rodman Webcast(November 06):
http://www.wsw.com/webcast/rrshq10/biotie/

Pipeline:

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.720.962 von BrauchGeld am 26.11.06 12:35:26

Bioties partner Somaxon präsentierte in juli positive daten !

http://www.somaxon.com/media/pdf/press2006/SOMX_Nalmefene_Sm…

Somaxon Pharmaceuticals Reports Positive Results From a Pilot Phase 2 Study of Oral Nalmefene in Smoking Cessation
SAN DIEGO, CA – July 26, 2006 − Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that oral nalmefene hydrochloride, an opiate antagonist under development by the company, demonstrated positive results in a pilot Phase 2 clinical trial for smoking cessation. In a single center, randomized, placebo-controlled study in which 76 smokers were enrolled, patients in the nalmefene 40mg group demonstrated numerically higher abstinence rates at all timepoints relative to placebo. Patients in the nalmefene 80mg group did not consistently achieve abstinence rates that were numerically superior to placebo. The study was not powered to demonstrate statistical significance.
Nalmefene was generally well tolerated, with an adverse event profile similar to that observed in studies previously conducted with nalmefene. The most commonly reported adverse events were insomnia and nausea. The adverse events tended to be transient in nature and largely resolved after the first week on study drug. Elevation in liver enzymes was observed with a similar frequency in all groups.

Somaxon’s Chief Medical Officer Phil Jochelson, MD commented, “We are encouraged by the results of our first smoking cessation clinical study which was designed to be exploratory in nature. We are intrigued with the observation that the nalmefene 40 mg treated patients maintained higher abstinence rates relative to placebo.”

Ken Cohen, Somaxon’s President and Chief Executive Officer commented, “Nalmefene is a promising compound. We are currently studying this product in a large clinical trial for the treatment of pathological gambling. We intend to await the results of that trial, which we expect early next year, before we determine our further clinical development plans. The results of this pilot smoking cessation trial give us the opportunity to potentially develop nalmefene for multiple indications in large markets with unmet medical needs.”

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.720.962 von BrauchGeld am 26.11.06 12:35:26

Das potential für Nalmefene gegen Spielsucht ist immens da es auch keine produkte für diesen bereich gibt.
Wenn die ergebnisse in Dezemeber positiv sind erwarte ich schon einen gewaltigen kurssprung !

Hier ein älterer Artikel:
http://www.somaxon.com/media/pdf/press2004/SanDiegoTribune_N…

A winning therapy?

S.D. firm hopes to market a drug to treat gambling addiction
By Penni Crabtree
STAFF WRITER
December 31, 2004

Although there are no sure bets in drug development, Somaxon
Pharmaceuticals is rolling the dice on a promising prospect: a
medicine to treat gambling addiction.
The privately held San Diego specialty drug company will begin
late-stage Phase 3 human study of the drug, nalmefene, next year.
In November, Somaxon agreed to pay up to $13.2 million to
Finnish drugmaker Biotie Therapies for rights to develop and sell
the drug in the United States as a treatment for pathological
gambling and other impulse control disorders.
"Given the size and growth of the gambling industry, and the
portion of people who can't control gambling impulses, we think
the market is pretty substantial," said Kenneth Cohen, chief
executive of Somaxon.
There is no approved drug for pathological gambling. Some
psychiatrists prescribe anti-depressants with mixed success, but
more common treatments are psychological counseling or
Gamblers Anonymous, a support group similar to Alcoholics Anonymous.
Yet some studies indicate that high numbers of gamblers – as many as 90 percent – drop out of GA by
the end of their first year, and often after the first or second visit.
Psychiatrists agree there is a need for more effective therapies to treat gambling addicts, in part because
the opportunities to gamble are growing – almost every state now has some form of legalized gambling,
whether it's lottery tickets, Indian casinos or off-track betting. But research in the field of impulse
control disorders – such as pathological gambling and kleptomania, or compulsive stealing – lags far
behind other, related areas.
"The field of gambling research is two to three decades behind that of substance abuse," said Dr. Marc
Potenza, assistant professor of psychiatry at Yale University's School of Medicine and director of the
Problem Gambling Clinic. "Mental health disorders carry a stigma in society, and addictions tend to
carry an even greater stigma.
"For many years, addictive behavior like gambling has been viewed as a sin or a vice," said Potenza,
who is a consultant for Somaxon. "It is only recently that people have begun to think about the
biological mechanisms that might predispose someone to develop problems with gambling."
Nalmefene, a drug that is already approved for use in reversing the effects of anesthesia, is thought
inhibit some of the mechanisms that researchers theorize are involved in impulse disorders.
The drug is a so-called opioid receptor antagonist, a
substance that blocks certain receptors in the brain
involved with the production of dopamine, a chemical
messenger that helps the brain process experiences of
pleasure and reward.
In the case of a problem gambler, the pleasurable
feeling experienced with a winning hand of poker is the
result of dopamine release, some researchers theorize.
If so, a drug that blocks the opioid receptors could
reduce feelings of pleasure and reward, and the craving
to continue the behavior that produces those feelings.
In a Phase 2 study of nalmefene, gamblers treated with
the drug reduced their gambling behavior and urges, compared with gamblers who took a dummy
"placebo" pill, according to Dr. Jon Grant, a Brown University psychiatrist who ran the clinical trial.
"It has shown very strong promise in being a helpful medication for gambling addiction," said Grant, a
Somaxon consultant and head of the Impulse Control Disorders Clinic in Rhode Island. "It's not a magic
pill. No one treatment can be magic for everyone, but for people who gamble because they have strong
urges it appears to be helpful."
Psychiatrists estimate that 1 to 2 percent of the general population are pathological gamblers, so
nalmefene, if successful, would likely find a small but profitable niche market.
Somaxon itself is a niche play: unlike biotech companies that discover new drugs, develop them and test
them from mouse to man, a specialty pharmaceutical company is essentially a marketing plan looking
for a drug to sell.
The company, which employs 11, was founded by a handful of consultants and former managers from
companies such as San Diego County's CancerVax and Women First HealthCare, a specialty
pharmaceutical company that declared bankruptcy this year.
Cohen said he and his fellow co-founders were encouraged by biotech veteran David Hale, chief
executive of CancerVax, to start the company. Hale eventually became an investor and serves as
Somaxon board chairman.
As with most specialty pharmaceutical companies, Somaxon takes some of the risk out of drug development by licensing already approved drugs from other companies, or finding new uses for old,
established drugs. Somaxon is also testing a formulation of doxepin, a drug already approved as a
treatment for depression, as a possible sleeping pill.
"Drug discovery takes a long time and has very big risk," Cohen said. "We wanted to start somewhat closer to the finish line, which is where the investment community wants companies to be."

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.720.962 von BrauchGeld am 26.11.06 12:35:26

Und heute wieder 32% plus auf 1,38 € vielen dank Biotie

27.11.2006

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 27 November 2006, at 5.50 p.m


H. Lundbeck A/S and Biotie Therapies Corp. have today signed an agreement on worldwide rights for nalmefene, excluding North America, Mexico, UK, Ireland, Turkey, and South-Korea. Under the terms of the agreement, BioTie has granted Lundbeck an exclusive license to market and distribute nalmefene as a prescription medicine for the treatment of substance abuse disorders and impulse control disorders.

Under the terms of the agreement, BioTie will receive an execution fee of EUR 15 million, of which EUR 10 million is payable on signing. The license enters into force in 2007. In total, BioTie is eligible for up to EUR 88 million in upfront and milestone payments plus royalty on sales. Lundbeck will be responsible for manufacturing and registration of the product in its territory.

BioTie has recently announced that it has submitted the first Marketing Authorisation Application on nalmefene for the treatment of alcohol dependence to the Medicines and Healthcare products Regulatory Authority (MHRA) in the UK. UK acts as reference in the Mutual Recognition Process for EU approval.

Timo Veromaa, President and CEO of BioTie, said: "We are extremely pleased to have Lundbeck as our partner for nalmefene. Lundbeck is a global leader in therapeutics for psychiatric disorders, which makes it an ideal partner for BioTie. With this agreement we now have partnered the product worldwide and expect it to generate significant revenues to the company in the long term."

Claus Bræstrup, President and CEO of H. Lundbeck A/S, said: "Nalmefene has a significant potential for helping patients with alcohol abuse. Alcohol abuse is comorbid among patients suffering from depression and schizophrenia as well as other psychiatric disorders and alcohol abuse constitute a major health and social problem."

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.720.962 von BrauchGeld am 26.11.06 12:35:26

Inzwischen 67% plus auf 1,74 €

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.720.962 von BrauchGeld am 26.11.06 12:35:26

und wieder 40% plus auf 2,30€ aktuell boah was ne granate